Effective site concentration of remifentanil inhibiting hypertension following endotracheal intubation using videolaryngoscope during induction with remimazolam
Not Applicable
Recruiting
- Conditions
- Diseases of the ear and mastoid process
- Registration Number
- KCT0008697
- Lead Sponsor
- Bundang CHA General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
Korean patients between the ages of 19 and 65 who are classified as American Society of Anesthesiology Classes 1 and 2 under general anesthesia
Exclusion Criteria
Allergy to study drug, acute narrow-angle glaucoma, sleep apnea syndrome, alcohol or drug dependence, galactose or lactase deficiency, dextran 40 hypersensitivity, heart, lung, kidney, liver, cerebrovascular system, Psychiatric patients, pregnant women, lactating women, foreigners, others American Society of Anesthesiologists Body Classification 3 or higher
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effective site concentration of remifentanil (EC95) that secures hemodynamic stability in 95% of patients after endotracheal intubation (blood pressure or heart rate measured 1 minute after endotracheal intubation do not rise by more than 20% of the reference value)
- Secondary Outcome Measures
Name Time Method Effective site concentration of remifentanil (EC50) that secures hemodynamic stability in 50% of patients after endotracheal intubation (blood pressure or heart rate measured 1 minute after endotracheal intubation do not rise by more than 20% of the reference value)